Keywords: b-ms, better, news, pipeline, antipsychotic, data, hiv
B-MS has better news on pipeline with antipsychotic data and HIV drug filing
Article | 03 June 2002
Bristol-Myers Squibb, which has recently suffered some hefty productdisappointments with its antihypertensive drug Vanlev (omapatrilat) and colorectal cancer treatment Erbitux ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
